Dispensing and Protecting the Blind

Part of Clinical Research Coordinator (CRC) Training: Investigational Product at the Site.

About 7 minutes. Free, in your language, no account needed.

Why this matters

Dispensing is the moment the protocol stops being a document and becomes medicine in somebody's hand. It is also the moment with the least time in it. The participant is in the room, the visit is running late, the window closes today, and the decision in front of you takes seconds.

Almost every serious product error at a site happens here, and almost all of them share one feature: somebody noticed that something did not match, and dispensed anyway.

Module 4 covered randomization and blinding as study design. This lesson is about what you do with them at the window.

Before you dispense

Four things are true before any product leaves the shelf. Check them in this order, because each one makes the next one meaningful.

The participant is eligible and still enrolled. Confirmed at screening, and not withdrawn or on hold since.

The visit is within its window, or the deviation is already documented and the investigator knows.

The assignment came from the system, not from you. Randomization and kit assignment come from the IRT. You do not choose which kit; you dispense the one the system names.

The investigator's authorization exists in whatever form the protocol requires — a prescription, a signed order, or the delegated arrangement your site works to. E6(R3) §2.10.6 requires the product to be used in accordance with the protocol, and the investigator owns that decision.

The three-way check

At the window itself, three things must agree:

Check the expiry date on the pack, not on the packing list.

If all three agree, dispense and record it contemporaneously: what was dispensed, to whom, when, by whom, and how much. That is the §2.10.3 requirement, and "contemporaneously" means at the window, not at the end of the clinic.

When they do not agree

If the label and the system disagree — the pack in your hand is not the number the IRT assigned, or the label is damaged, unreadable, or shows an expiry that has passed — stop.

Not "check later". Not "dispense this one and correct the record". Stop, keep the pack, and do not give it to the participant.

Then, in order: tell the investigator; contact the sponsor or the IRT helpdesk to resolve the assignment; and document what you found, at the time, before anything is corrected. If resolving it means the participant cannot be dosed today, that is a protocol deviation, and a deviation is a smaller problem than a participant on the wrong treatment.

The pressure is real: the participant has taken a day off work, the window closes tonight, and the mismatch is probably a system lag. It is still not your call. Dispensing a kit the system did not assign can unblind a participant, put them on the wrong arm, and make their data unusable — and no amount of later documentation undoes it.

Protecting the blind

In a double-blind trial like VT-201, the blind is protected by the packaging and by the people. The packaging is the sponsor's job. The people are yours.

What that means at the site:

Explaining it to the participant

E6(R3) §2.10.7 asks that participants have the product's correct use explained to them, and that their understanding and compliance are checked periodically. This is a real teaching task, not a handover of a leaflet.

Cover how much, when, with or without food, what to do about a missed dose, how to store it at home, and what to bring back. Ask them to tell you the plan in their own words rather than asking whether they understand. Then write down that you did it.

At the next visit, check compliance: count what comes back against what was dispensed and what should have been taken. A participant taking noticeably more or less than the protocol expects is a finding worth raising with the investigator, and often a conversation worth having with the participant.

When a dispensing error happens

They happen. The response is what is judged.

  1. The participant's safety first. Tell the investigator immediately; they decide on clinical management and whether the participant continues.
  2. Secure the product involved and do not put it back into stock.
  3. Report to the sponsor — an incorrectly dispensed product is a protocol deviation and may have safety and data consequences the sponsor needs to assess.
  4. Document what happened, contemporaneously and factually, without editing the original entries.
  5. Look at why, once the participant is safe. A near-identical kit number, an interruption at the window, a system that was slow — these repeat unless something changes.

In practice

Subject 041 attends a VT-201 visit on the last day of her window. The IRT assigns kit 2287. Nadia takes 2287 from the shelf and sees that the label reads 2278.

Two of the four visits in the clinic are already running late, and the participant has arranged childcare. The obvious reading is a transposition somewhere and the two kits are probably from the same batch.

Nadia does not dispense. She sets both kits aside, tells Dr. Osei, and calls the IRT helpdesk from the room. The helpdesk finds that 2278 was assigned to a different participant three weeks earlier at another site and had been shipped to Northside in error; 2287 is in the same shipment, one row down on the shelf. She locates 2287, repeats the three-way check, and dispenses.

The visit runs forty minutes late. The alternative — a participant dosed from another participant's assigned kit — would have cost a protocol deviation report, a sponsor investigation, and quite possibly that participant's data.

Key takeaways